Twist Bioscience — Fiscal 2026 Earnings Summary

Twist Bioscience reported record full-year fiscal 2026 revenue of $459.4 million, representing a 22% increase over the prior year, with fourth-quarter revenue reaching $126.6 million. The company achieved a gross margin of 52.4% for the full year and posted positive adjusted EBITDA of $2.2 million in the fourth quarter. Fiscal 2027 revenue guidance is set between $550 million and $560 million, reflecting an expected 21% year-over-year growth at the midpoint. As of September 30, 2026, the company maintained a cash position of approximately $582 million while expanding its customer base to roughly 4,100 clients.